Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics
Armored, iPSC-derived CAR macrophages for pancreatic cancer
BioCentury | Dec 20, 2022
Deals
Tmunity buyout gives next building block to Gilead’s Kite
Cell therapy business adds armored CAR T platform, handful of therapies, but won’t advance prostate cancer program
BioCentury | Dec 9, 2020
Product Development
Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim
Amgen readies sotorasib for FDA Amgen Inc. (NASDAQ:AMGN) said it plans to submit an NDA for its closely watched KRAS inhibitor sotorasib by year-end to treat locally advanced or
BioCentury | Jan 25, 2020
Targets & Mechanisms
CAR T strategies for cracking the code in solid tumors
The targets and indications CAR T developers are exploring to get to efficacy in solid tumors
BioCentury | Jun 1, 2019
Product Development
ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts
BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors
BioCentury | Dec 10, 2016
Product Development
Rules of the road
Why early management of CRS may cut CAR T toxicity without denting efficacy
BioCentury | Jul 18, 2016
Product Development
ROCKET resumes
Pondering reasons for neurotoxicity in Juno's CAR T leukemia trial
Items per page:
1 - 10 of 37